Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $14 from $17 and keeps a Buy rating on the ...

Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to ful ...

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

Prothena Biosciences Ltd. and Vanderbilt University have jointly discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.